Literature DB >> 19702600

Wolff-Parkinson-White syndrome and atrioventricular nodal re-entry tachycardia in a Swedish population: consequences on health-related quality of life.

Ulla Walfridsson1, Anna Strömberg, Magnus Janzon, Håkan Walfridsson.   

Abstract

BACKGROUND: Living with paroxysmal supraventricular tachycardia affects a patient's whole life situation, but few studies have addressed health-related quality of life (HRQOL) aspects in these patients. The aim was therefore to describe HRQOL in patients with atrioventricular nodal re-entry tachycardia (AVNRT) or Wolff-Parkinson-White (WPW) syndrome, referred for radiofrequency ablation (RF-ablation), compared to age- and gender-matched Swedish reference groups.
METHODS: HRQOL was assessed with SF-36 and EuroQol (EQ-5D and EQ-VAS) and the patients were asked disease-specific questions.
RESULTS: The 97 patients with AVNRT [53 +/- 16 years of age/65 women] and 79 patients with WPW [42 +/- 15 years of age/26 women] exhibited significantly lower HRQOL scores in SF-36 in the same seven of the eight scales: Physical functioning (PF), role-physical (RP), social functioning (SF), role-emotional (RE), general health (GH), vitality (VT), and mental health (MH) while there was no difference in bodily pain (BP) compared to their respective age- and gender matched Swedish reference group. HRQOL scores were lower for patients with AVNRT compared to WPW in the areas of PF (P < 0.001), BP (P < 0.05), and GH (P < 0.01) in SF-36, and the same was found in EQ-VAS (64.8 vs. 71.2, P < 0.05). Occurrence of episodes of tachycardia more often than once a month compared to less frequently than once a month was associated with significantly lower HRQOL in all eight scales in SF-36 (GH, RE, MH: P < 0.01 and PF, RP, BP, VT, SF: P < 0.001) and EQ-5D index (P < 0.001) and EQ-VAS (P < 0.05) Arrhythmia duration longer than one hour compared to patients with shorter duration of the tachycardia-affected GH in SF-36 negatively (P < 0.05). Patients who experienced symptoms not only during activity but also at rest scored lower in SF-36 GH (P < 0.01) and SF (P < 0.05).
CONCLUSION: Measuring HRQOL in patients with WPW or AVNRT is an important way to evaluate and describe these patients' life situation. These conditions were found to have a pronounced negative impact on HRQOL. The frequency of arrhythmia occurrence is one important factor to consider when setting priorities for treatment with RF-ablation.

Entities:  

Mesh:

Year:  2009        PMID: 19702600     DOI: 10.1111/j.1540-8159.2009.02476.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  10 in total

1.  New insights into the clinical signs of supraventricular tachycardia: The "sign of lace-tying".

Authors:  Dominique Blommaert; Fabien Dormal; Olivier Deceuninck; Olivier Xhaet; Elisabeth Ballant; Luc De Roy
Journal:  Ann Noninvasive Electrocardiol       Date:  2017-06-08       Impact factor: 1.468

2.  Development and validation of a new Arrhythmia-Specific questionnaire in Tachycardia and Arrhythmia (ASTA) with focus on symptom burden.

Authors:  Ulla Walfridsson; Kristofer Arestedt; Anna Stromberg
Journal:  Health Qual Life Outcomes       Date:  2012-04-30       Impact factor: 3.186

3.  Symptomatic improvement after catheter ablation of supraventricular tachycardia measured by the arrhythmia-specific questionnaire U22.

Authors:  Milos Kesek; Folke Rönn; Titti Tollefsen; Niklas Höglund; Ulf Näslund; Steen M Jensen
Journal:  Ups J Med Sci       Date:  2010-11-16       Impact factor: 2.384

4.  Differences in quality of life, anxiety and depression in patients with paroxysmal atrial fibrillation and common forms of atrioventricular reentry supraventricular tachycardias.

Authors:  Louiza Lioni; Konstantinos Vlachos; Konstantinos P Letsas; Michael Efremidis; Dimitrios Karlis; Dimitrios Asvestas; Vasilios Kareliotis; Sotirios Xydonas; Nikolaos Dimopoulos; Panagiotis Korantzopoulos; Athanasios Trikas; Antonios Sideris
Journal:  Indian Pacing Electrophysiol J       Date:  2014-10-06

5.  Patient's age rather than severity of the arrhythmia influences the cost of medical treatment of atrioventricular nodal or atrioventricular reciprocating tachycardia.

Authors:  Michal M Farkowski; Mariusz Pytkowski; Aleksander Maciag; Dominik Golicki; Ilona Kowalik; Marcin Czech; Piotr Rucinski; Hanna Szwed
Journal:  J Interv Card Electrophysiol       Date:  2016-08-03       Impact factor: 1.900

6.  Assessment of the neutrophil/lymphocyte ratio in patients with supraventricular tachycardia.

Authors:  Mesut Aydın; Abdülkadir Yıldız; Murat Yüksel; Nihat Polat; Adem Aktan; Yahya İslamoğlu
Journal:  Anatol J Cardiol       Date:  2016-01       Impact factor: 1.596

7.  Impact of Radiofrequency Ablation and Antiarrhythmic Medications on the Quality of Life of Patients with Supraventricular Tachycardias: Preliminary Validation of the Greek Version of the Umea22 (U22) Questionnaire.

Authors:  Philippe-Richard Domeyer; Smaragda Ch Giannakidou; Panagiota Kyriakou; Vasiliki Katsari; Antonios P Antoniadis; Ioannis K Lagos; Nikolaos Fragakis; Agoritsa Varaklioti; Vassilios P Vassilikos
Journal:  Biomed Res Int       Date:  2018-10-09       Impact factor: 3.411

8.  Evaluation of medical and psychological parameters of quality of life in supraventricular tachyarrhythmia children. A comparison with healthy children.

Authors:  Emilia Szafran; Artur Baszko; Anna Bukowska-Posadzy; Tomasz Moszura; Bożena Werner; Aldona Siwińska; Maciej Banach; Jarosław Walkowiak; Waldemar Bobkowski
Journal:  Arch Med Sci       Date:  2016-08-24       Impact factor: 3.318

9.  Patients' Experiences of Living with Atrial Fibrillation: A Mixed Methods Study.

Authors:  Marie Stridsman; Anna Strömberg; Jeroen Hendriks; Ulla Walfridsson
Journal:  Cardiol Res Pract       Date:  2019-12-03       Impact factor: 1.866

10.  Health care centre and emergency department utilization by patients with episodes of tachycardia.

Authors:  Ann-Katrin Nordblom; Gabriella Norberg Boysen; Mia Berglund; Anna Kjellsdotter
Journal:  BMC Cardiovasc Disord       Date:  2022-03-23       Impact factor: 2.298

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.